Osteochondrodysplasia
Therapeutic area
Rheumatology
Rare disease
No
- Definition
- A term referring to disorders characterized by abnormalities in the development of bones and cartilage.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Osteochondrodysplasia
- Therapeutic area
- Rheumatology
- osteochondrodysplasia
- congenital skeletal dysplasia
- cartilage development disorder
- congenital anomaly of cartilage
- skeletal dysplasia
- All therapeutic areas
- Rheumatology
Sources for recorded values
- Severity
- Severe
- Developmental
- Genetic
- Hereditary
Sources for recorded values
- MONDO ID
- MONDO:0005516
- Parent condition
- MONDO:0005497
Related records
Broader conditions (13)
- Bone development disease
- Bone disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disorder of development or morphogenesis
- Hereditary disease
- Human disease
- Musculoskeletal system disorder
- Skeletal dysplasia
- Skeletal system disorder
Narrower conditions (255)
- Acheiropody
- Achondrogenesis
- Achondrogenesis type IA
- Achondrogenesis type IB
- Achondrogenesis type II
- Achondroplasia
- Acrocapitofemoral dysplasia
- Acromesomelic dysplasia
- Acromesomelic dysplasia 1, Maroteaux type
- Acromesomelic dysplasia 2A
- Acromesomelic dysplasia 2B
- Acromesomelic dysplasia 2C, Hunter-Thompson type
- Acromesomelic dysplasia 3
- Acromesomelic dysplasia 4
- Acromesomelic dysplasia, Campailla Martinelli type
- Anauxetic dysplasia
- Anauxetic dysplasia 1
- Anauxetic dysplasia 2
- Anauxetic dysplasia 3
- Arterial tortuosity-bone fragility syndrome
Trials (22)
- A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
- A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- An Efficacy and Safety Study of Palovarotene for the Treatment of MO
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
- An Interventional Study of Infigratinib in Children With Hypochondroplasia
- Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia
- Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
- Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
- Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
- Prospective Clinical Assessment Study in Children With Hypochondroplasia
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia
- Study of Infigratinib in Children With Achondroplasia